Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer
13 juin 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer
13 juin 2022 07h45 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus to Present at the Jefferies Healthcare Conference
02 juin 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
26 mai 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Hosts Inaugural Investor Day
16 mai 2022 16h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), will host its Inaugural Investor Day at the Nasdaq MarketSite on Tuesday, May 17,...
Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting
16 mai 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients
13 mai 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer
11 mai 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus to Present at the UBS Global Healthcare Conference
10 mai 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results
29 avr. 2022 07h07 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $208.9 million for the first quarter 2022, representing an increase of 125.8% from the prior year period GAAP net income of $43.0 million for the first quarter 2022, compared to...